Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

AstraZeneca

Status: Enrolling

Conditions: Metastatic Breast Cancer

Treatments: Other: non-interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT07008963

D3615R00004

Details and patient eligibility

About

A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed

Enrollment: 50 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria (self-reported):

• Adult (over the age of 18 years)
• Diagnosed with HR+/HER2- metastatic breast cancer
• Received at least 1 week of capivasertib + fulvestrant (Patients will be invited to provide documents demonstrating the use of capivasertib. Patients will be able to participate even if unable to obtain such documentation)

Exclusion criteria (self-reported):

• Patients who had discontinued capivasertib for more than 6 months before the date of the interview
• Unable or unwilling to follow study procedures (including providing informed consent)
• Not proficient in spoken English, as assessed by the moderator
• Receiving capivasertib in a clinical trial setting
• Patients who are not able to recall instruction for administration of capivasertib in a manner consistent with the labeling (e.g. 4 days on followed by 3 days off)